Bristol-Myers Squibb has transformed itself into a diversified BioPharma leader. We have combined the passion and entrepreneurial spirit of a leading-edge biotech company with the experience and capabilities of a major pharmaceutical company. One of the ways we are doing this is through innovative partnerships with external companies led by our Business Development team.
Bristol-Myers Squibb has long since recognized that innovation happens everywhere and, as such, partnering has been for decades an important element of our strategy. We actively seek access to cutting-edge science that complements the innovative science coming out of our own labs as we work to deliver transformational medicines to patients. Our Business Development team collaborates closely with R&D and commercial to identify opportunities within our strategy that address areas of high unmet medical need across the spectrum of drug development, from discovery to late stage clinical trials to commercialization.
Our alliances partners encompass many types of organizations from around the world (companies, academia, consortiums) and different collaboration structures including in-licensing compounds, option agreements, clinical collaborations, and collaborations that access platform technologies, drug delivery systems, advances in pharmaco-genomics and biomarkers. We also have major collaborations involving some of our internally discovered assets. Bristol-Myers Squibb has a well-established record of successfully building partner discoveries into significant therapies, and we have a history of forming productive collaborations to jointly develop and commercialize brands. For a list of Bristol-Myers Squibb collaborations please see "Our Partners".
We invite you to explore the partnering section of our site for an overview of our commitment to partnering, the disease area programs and technologies we are looking for and how we might be able to combine our strengths to bring transformational medicines to the patients who need them.